Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Walsh

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
The Journal of Infectious Diseases|August 29, 2014
Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humansLindsey R Baden, Jinyan Liu, Hualin Li, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
Plos One|August 9, 2019
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 studyYehuda Z Cohen, Allison L Butler, Katrina Millard, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Annals of Internal Medicine|February 3, 2016
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized TrialLindsey R Baden, Etienne Karita, Gaudensia Mutua, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
The Journal of Infectious Diseases|August 29, 2014
Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humansLindsey R Baden, Jinyan Liu, Hualin Li, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
Plos One|August 9, 2019
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 studyYehuda Z Cohen, Allison L Butler, Katrina Millard, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Annals of Internal Medicine|February 3, 2016
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized TrialLindsey R Baden, Etienne Karita, Gaudensia Mutua, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Pageof 8